Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 12/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3543463 | 0.79 | SLC22A12 (0.35) | SLC22A12GCK | |
| SCHEMBL3539198 | 0.78 | NFE2L2 (0.42) | GCKTSHR | |
| SCHEMBL3544609 | 0.72 | S1PR4 (0.38) | GCK | |
| SCHEMBL3542130 | 0.71 | MPO (0.35) | GCK | |
| SCHEMBL2644698 | 0.70 | NFE2L2 (0.36) | GCK | |
| SCHEMBL2645858 | 0.70 | POLB (0.42) | SLC22A12PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3540210 | 0.69 | GCK (0.35) | GCK | |
| SCHEMBL2645411 | 0.68 | ALDH1A1 (0.34) | SLC22A12GCK | |
| SCHEMBL2646549 | 0.68 | GCK (0.36) | GCK | |
| SCHEMBL12924641 | 0.68 | NFE2L2 (0.47) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935890-B1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD KK (JP) | 2016-03-16 | — | — | EP | disclosed |
| US-7799820-B2 | 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20090118304-A1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1935890-A1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118304-A1 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | GCKR, GPR119, GCK | CCR2 1071/4885SLC22A12 1201/4885GCK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.